Johnson & Johnson Reports Q3 2026 Earnings with Mixed Performance Across Segments
Johnson & Johnson (JNJ) reported third-quarter earnings for fiscal year 2026, showing mixed results across its business segments. The company achieved $25.4 billion in worldwide sales, a 6% operational increase driven by strong performance from the Innovative Medicine segment. However, adjusted EPS fell to $2.59 due to dilution from recent acquisitions and collaborations. The MedTech division reported revenue of $8.6 billion with modest growth, while products like Tremfya saw significant sales increases—up 68.2% year-over-year. Darzalex also showed strong performance with a 15.6% increase in revenue. However, Stelara faced challenges from biosimilar competition and reported a 5.4% decline. Johnson & Johnson maintained its full-year guidance for sales between $100.5 billion to $100.9 billion and adjusted EPS of $11.05–$11.15, citing momentum in the base business.
Tickers: $JNJ
Topics: acquisitions medtech pharmaceuticals revenue_growth
Read the full article at Motley Fool
Part of the story JPMorgan Chase to Report Q3 2026 Earnings with Market Expecting Strong Performance (6 articles)